Admittedly, immunosuppressive induction therapy in renal transplantation (RT) has proved its place in the prevention of graft rejection, especially in patients at high immunological risk [1]. Several molecules have been put on the market. They act by different mechanisms. These molecules are generally antibodies that can target a single well-defined antigen (monoclonal antibody) or several antigens (polyclonal antibodies) whose role in the development of the rejection process has been well demonstrated.